# OnCo record paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022" ;
  schema:name "AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma"@en ;
  schema:description "Swapping bleomycin for the antibody-drug conjugate brentuximab vedotin in children's chemotherapy for advanced Hodgkin lymphoma cut the risk of relapse or death by 59 percent with no extra toxicity."@en ;
  schema:url <https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2206660>, <https://pubmed.ncbi.nlm.nih.gov/36322844/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2206660> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Castellino SM, Pei Q, Parsons SK, et al." ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:trials <https://onco.cc/trials/ahod1331/> ;
  onco:journals <https://onco.cc/journals/nejm/> .